SCHEMBL29487299

SCHEMBL29487299

C=C1c2c(Cl)ccc(O)c2C(O)=C2C(=O)[C@]3(O)C(O)=C(C(N)=O)C(=O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 12/20 0.78
KDM4E B2RXH2 10/20 0.78
USP2 O75604 9/20 0.78
RECQL P46063 8/20 0.78
HSD17B10 Q99714 8/20 0.78
HPGD P15428 8/20 0.78
MEN1 O00255 7/20 0.78
KMT2A Q03164 7/20 0.78
THRB P10828 6/20 0.78
MAPT P10636 6/20 0.78
ALDH1A1 P00352 6/20 0.78
L3MBTL1 Q9Y468 6/20 0.78
LMNA P02545 3/20 0.78
CASP1 P29466 1/20 0.78
CASP7 P55210 1/20 0.78
SMN1; SMN2 Q16637 1/20 0.78
NR1I2 O75469 2/20 0.75
MC4R P32245 1/20 0.75
SIRT5 Q9NXA8 1/20 0.75
POLB P06746 3/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23247761 1.00 TDP1 (0.78) TDP1KDM4EUSP2RECQLHSD17B10
Sulfosalicylic SCHEMBL29674900 0.89 TDP1 (1.00) TDP1KDM4EUSP2RECQLHSD17B10
SCHEMBL19555132 0.86 TDP1 (1.00) TDP1KDM4EUSP2RECQLHSD17B10
SCHEMBL26628251 0.86 TDP1 (1.00) TDP1KDM4EUSP2RECQLHSD17B10
SCHEMBL29537520 0.86 TDP1 (1.00) TDP1KDM4EUSP2RECQLHSD17B10
SCHEMBL30567156 0.86 TDP1 (1.00) TDP1KDM4EUSP2RECQLHSD17B10
SCHEMBL26597994 0.86 TDP1 (1.00) TDP1KDM4EUSP2RECQLHSD17B10
SCHEMBL12841672 0.85 TDP1 (0.62) TDP1KDM4EUSP2RECQLHSD17B10
Hydrochloric Acid SCHEMBL29413670 0.85 TDP1 (1.00) TDP1KDM4EUSP2RECQLHSD17B10
SCHEMBL1650332 0.85 TDP1 (0.62) TDP1KDM4EUSP2RECQLHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114902608-B Medical device, authentication server and method for authorizing a user to access a device via a device user interface 甘布罗伦迪亚股份公司 2025-05-23 CN claimed
CN-119254418-A Computer-implemented method and system for transferring access to digital assets 区块链控股有限公司 2025-01-03 CN claimed
CN-118381661-B Secure multiparty computing method, apparatus, device, medium and computer program product 浪潮(北京)电子信息产业有限公司 2024-09-03 CN claimed
CN-112204920-B Computer-implemented method and system for transferring access to digital assets 区块链控股有限公司 2024-09-03 CN claimed
CN-115016626-B Secure initiation via a system and power management microcontroller 美光科技公司 2024-08-16 CN claimed
CN-118381661-A Secure multiparty computing method, apparatus, device, medium and computer program product 浪潮(北京)电子信息产业有限公司 2024-07-23 CN claimed
CN-113032797-B Method for executing encryption operation in processing equipment 意法半导体股份有限公司 2024-06-14 CN claimed
CN-117857039-B Multiparty security computing method, device, equipment and medium 浪潮(北京)电子信息产业有限公司 2024-05-28 CN claimed
CN-117857039-A Multiparty security computing method, device, equipment and medium 浪潮(北京)电子信息产业有限公司 2024-04-09 CN claimed
CN-117176335-B Data tracking method based on alliance chain and related equipment 北京邮电大学 2024-03-15 CN claimed
CN-117176335-A Data tracking method based on alliance chain and related equipment 北京邮电大学 2023-12-05 CN claimed
CN-111758127-B Secret calculation device and method thereof secret calculation authentication system and recording medium 日本电信电话株式会社 2023-08-08 CN claimed
CN-116569169-A Security management for ferroelectric memory devices 美光科技公司 2023-08-08 CN claimed
CN-122087882-A Storage device and method for generating device identifier 2026-05-26 CN disclosed
US-20260097092-A1 PHARMACEUTICAL COMPOSITION CONTAINING MITOCHONDRIA-TARGETING COMPOUND AS ACTIVE INGREDIENT FOR TREATING MACULAR DEGENERATION ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-04-09 US disclosed
CN-119977722-A Water-soluble fertilizer containing silkworm chrysalis protein and preparation method and application thereof 黑龙江宋世生物科技有限公司 2025-05-13 CN disclosed
WO-2022124739-A1 NUCLEIC ACID MOLECULE FOR INDUCTION OF ASYMMETRIC RNAI FOR INHIBITING EXPRESSION OF ROR-BETA 올릭스 주식회사 2022-06-16 WO disclosed
CN-114586313-A System and method for signing information GK8 有限公司 2022-06-03 CN disclosed
CN-109310526-B Pramipexole transdermal patch system and method of use 全崴生技股份有限公司 2022-05-17 CN disclosed
US-11291656-B2 Pramipexole transdermal delivery system and uses thereof Transwell Biotech Co., Ltd. (TW) 2022-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260097092-A1 PHARMACEUTICAL COMPOSITION CONTAINING MITOCHONDRIA-TARGETING COMPOUND AS ACTIVE INGREDIENT FOR TREATING MACULAR DEGENERATION ARG2, NLN, RHOT2 TDP1 1165/4885KDM4E 2989/4885USP2 4550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.